エピソード

  • Multidisciplinary Conversations with Radiation Oncologist Carien Creutzberg

    Multidisciplinary Conversations with Radiation Oncologist Carien Creutzberg
    2024/10/30

    IGCS Education360 Radiation Oncology Workgroup, chaired by Dr. Pearly Khaw, interview with Professor Carien Creutzberg, recipient of the IGCS 2024 Lifetime Achievement Award. She discusses her pioneering work and the significance of international collaboration. Creutzberg reflects on the evolution of research questions in clinical trials, the integration of molecular and immunotherapy advancements, and the importance of multidisciplinary teams in enhancing patient care and treatment outcomes.
    続きを読む 一部表示
    19 分
  • Selinexor in Maintenance Therapy After Systemic Therapy for Patients with p53 Wild-Type

    Selinexor in Maintenance Therapy After Systemic Therapy for Patients with p53 Wild-Type
    2024/05/14
    Listen to Dr. Robert Coleman (USA) and Dr. Floor Backes (USA) discuss a new trial in progress enrollment information for advanced and recurrent endometrial cancer - Selinexor in Maintenance Therapy After Systemic Therapy for Patients with p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma: XPORT-042. Video available at IGCS Education360 Learning Portal - https://edu360.igcs.org/URL/AU_05152024
    続きを読む 一部表示
    21 分
  • Early Career Workshop 2022 - Hear from the Gynecologic Oncology Editors

    Early Career Workshop 2022 - Hear from the Gynecologic Oncology Editors
    2022/12/15
    Let’s Hear from the Gynecologic Oncology Editors of: • Obstetrics & Gynecology - Jason Wright (USA) • American Journal of Obstetrics and Gynecology- Larry Copeland (USA) • Gynecologic Oncology and Gynecologic Oncology Reports - Susan Modesitt (USA) • International Journal of Gynecological Cancer - Pedro Ramirez (USA) Moderator: Rhonda Farrell (Australia)
    続きを読む 一部表示
    1 時間 4 分
  • The ABCs of ADCs

    The ABCs of ADCs
    2021/12/08
    In this episode of the IGCS Education 360 Podcast entitled: The ABCs of ADCs, Dr. Brad Monk, from the Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network) and the University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph's Hospital Phoenix, USA and Medical Director US Oncology Research Network - Gynecologic Program is joined by Dr. Kathleen Moore, Virginia Kerley Cade Endowed Chair in Cancer Developmental Therapeutics Associate Director Clinical Research, Director, Oklahoma TSET Phase I Program, Stephenson Cancer Center and Associate Professor, Section of Gynecologic Oncology At the University of Oklahoma Health Sciences Center to talk about Antibody-Drug Conjugate or ADCs. ADC’s are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. In this episode you will learn the following: • How exactly ADCs work? • What are the targets for ADCs? • The differences between ADC, MOA, and the differences between some of the ADCs – high DAR, and the controlled bystander effect • Importance of an optimal diagnostic assay (H-score vs PS2+ vs TPS) NS the importance of a correct dosing regimen • And finally payload in relation to ADC’s and current ongoing studies.
    続きを読む 一部表示
    27 分